文章：

慢性淋巴细胞白血病：靶向药物时代的不良事件管理

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

原文发布日期：24 May 2024

DOI: 10.3390/cancers16111996

类型: Article

开放获取: 是

英文摘要：

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton’s Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors (BCL-2is). These agents target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which has led to improved progression-free and overall survival rates. This advancement promises enhanced disease control and potentially normal life expectancy for many patients. However, the journey is not without challenges, as these TAs are associated with a range of adverse events (AEs) that can impact treatment efficacy and patient quality of life. This review focuses on detailing the various AEs related to TA management in CLL, evaluating their frequency and clinical impact. The aim is to present a comprehensive guide to the effective management of these AEs, ensuring optimal tolerability and efficacy of TAs. By reviewing the existing literature and consolidating findings, we provide insights into AE management, which is crucial for maximizing patient outcomes in CLL therapy.

摘要翻译： 

随着布鲁顿酪氨酸激酶抑制剂（BTKis）和BCL-2抑制剂（BCL-2is）等靶向药物的问世，慢性淋巴细胞白血病（CLL）的治疗格局发生了深刻变革。这些药物针对CLL的关键细胞通路，较传统化学免疫疗法具有更优疗效，从而显著改善了患者的无进展生存期和总生存期。这一进展为众多患者带来了更好的疾病控制前景，甚至可能实现接近正常的预期寿命。然而，治疗过程仍面临挑战，因为靶向药物会引发一系列可能影响疗效及患者生活质量的不良事件。本综述重点详述CLL靶向治疗相关的各类不良事件，评估其发生频率与临床影响，旨在为有效管理这些不良事件提供全面指导，从而确保靶向药物的最佳耐受性和疗效。通过系统回顾现有文献并整合研究结果，本文深入探讨不良事件管理策略，这对优化CLL治疗的患者结局至关重要。

原文链接：

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents